Destination Breathe Easy: Managing Chronic Obstructive Pulmonary Disease While Emphasizing Patient Education
Released On
February 27, 2024
Expires On
February 27, 2025
Media Type
Internet
Completion Time
60 minutes
Specialty
Primary Care, Pulmonology
Topics
Cardiovascular Disease, Respiratory
This activity is provided by Med Learning Group.
![](https://store.continuingeducation.com/media/wysiwyg/FCME/2023-04-03-01/MLG_logo.png)
This activity is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc., and Sanofi.
Credit Available
- Physicians - 1.0 AMA PRA Category 1 Credit™
- Nurses - 1.0 ANCC Contact Hour
All other healthcare professionals completing this course will be issued a statement of participation.
Target Audience
This educational activity is specifically designed for US-based pulmonologists involved in the diagnosis and management of patients with COPD.
Program Overview
This program is designed to enhance clinicians’ ability to explain the roles of interleukins (IL)-4/13, IL-33 and other pro-inflammatory cytokine signaling pathways in the etiopathogenesis of chronic obstructive pulmonary disease (COPD) and its disease mechanism, discuss data from clinical studies investigating the clinical profiles of emerging therapies for the treatment of COPD, and describe multidisciplinary, shared decision-making strategies to improve patient-specific communication and education throughout each step of the care continuum of COPD.
Learning Objectives
- Explain the roles of interleukins (IL)-4/13, IL-33 and other pro-inflammatory cytokine signaling pathways in the etiopathogenesis of COPD and its disease mechanism
- Discuss data from clinical studies investigating the clinical profiles of emerging therapies for the treatment of COPD
- Describe multidisciplinary, shared decision-making strategies to improve patient-specific communication and education throughout each step of the care continuum of COPD
Faculty
![Nicola Hanania, MD, MS](https://store.continuingeducation.com/media/wysiwyg/FCME/2024-02-20-01/Hanania_Nicola.jpg)
Nicola Hanania, MD, MS
Professor of Medicine
Director, Airways Clinical Research Center
Senator, Clinical Science Representative
BCM Faculty Senate
Baylor College of Medicine
Houston, Texas
Accreditation Statement
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Physicians Credit Designation
Med Learning Group designates this virtually live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the virtually live activity.
Nurses (ANCC) Credit Designation
Med Learning Group designates this activity for a maximum of 1.0 ANCC contact hours.
Disclosures of Conflicts Of Interest
According to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and all of the relevant financial relationships listed for these individuals have been mitigated.
Disclosure of relevant financial relationships are as follows:
Nicola Hanania, MD, MS Discloses that he has received consulting fees from Sanofi/Regeneron, Genentech, AstraZeneca, GSK, and Boehringer Ingelheim; he has received research funding from GSK, Sanofi, AstraZeneca, and Genentech.
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer. The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
Anne Knieriem RN, MSN, has nothing to disclose.
Michael Milano, MD, has nothing to disclose.
A medical reviewer from CME Peer Review, LLC, has nothing to disclose.
Caitlin Rothermel, MPH, Medical Director for Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
Andi Koral, Program Manager for Med Learning Group, has nothing to disclose.
Aimee Meissner, Accreditation and Outcomes Coordinator, has nothing to disclose.
Planners for this activity have no relevant financial relationships with any ineligible companies.
Instructions for Participation and Credit
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:
- Read the CME/CE information and faculty disclosures.
- Participate in the online activity.
- Submit the post-test (achieving a passing score of 70%) and the evaluation form.
Certificates will be emailed to the participant.
Course Viewing Requirements
Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclosure of Unlabeled Use
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture the faculty may mention the use of medications for both US Food and Drug Administration (FDA)-approved and non-FDA-approved indications.
Disclaimer
Med Learning Group makes every effort to develop CE activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
Contact Information
For CME questions please contact: [email protected].
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at: https://www.medlearninggroup.com/privacy-policy/
Americans with Disabilities Act
Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
Content - Copyright © 2023 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
![](https://store.continuingeducation.com/media/wysiwyg/FCME/2024-02-20-01/RD_65L_Footer.jpg)